NCT06064890 · Phase 1 · RECRUITING
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
This Phase 1 trial is testing AVB-101, a gene therapy delivered directly into the brain through a surgical procedure. It targets a specific inherited form of frontotemporal dementia caused by mutations in the GRN gene, which causes low progranulin protein levels and neuron death. Phase 1 means the focus is on safety first. Researchers also want to see if one treatment can restore progranulin to normal levels. There is no placebo — everyone receives the treatment.
You may qualify if
- Male or female, 30 to 75 years of age
- Carriers of a pathogenic GRN mutation
- FTD as evidenced by CDR + NACC FTLD global score of 0.5, 1.0, or 2.0
- Presence of 1 or more of the criteria for diagnosis of possible bvFTD or PPA
- Able and willing to comply with all procedures and the study visit schedule
- Able and willing to give written informed consent prior to study participation, and agree to designate a legal representative to act on their wishes to continue participation should they lose capacity to consent at some point during the study OR If, in the Investigator's opinion, the subject lacks capacity to consent, written informed consent of their legal representative must be obtained in accordance with local laws, regulations, and/or customs. In countries where local laws, regulations, and/or customs do not permit subjects who lack capacity to consent to participate in this study, these subjects will not be enrolled
- An identified, informed study partner who is able and willing to support the participant in the study and to provide assessments of the participant during the study
You're excluded if
- Severe dementia, defined as CDR + NACC FTLD global score of 3.0, or other symptoms that preclude the ability to comply with study procedures and/or pose unacceptable safety risk to the subject
- Any concurrent disease that may cause cognitive impairment unrelated to mutations in the GRN gene, such as other causes of dementia, neurosyphilis, hydrocephalus, stroke, small vessel ischemic disease, uncontrolled hypothyroidism, or vitamin B12 deficiency
- Clinically significant abnormality on MRI at Screening considered to be a contraindication to Intrathalamic infusion
- Surgically significant pattern of brain atrophy on MRI at Screening that interferes with planned neurosurgical trajectory
- Previous treatment with any gene or cell therapy
- Previous treatment with any investigational medicinal product (IMP) within 60 days or 5 half-lives (whichever is longer) prior to study drug treatment
- Concomitant disease, any clinically significant laboratory abnormality, or treatment which, in the opinion of the Investigator, may pose an unacceptable safety risk to the participant or interfere with study conduct or the participant's ability to comply with study procedures including neurosurgical administration under anesthesia
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-04-13